Skip to main content
Premium Trial:

Request an Annual Quote

Codex DNA: Synthetic SARS-CoV-2 B.1.617

Codex DNA has released a full-length synthetic genome for the SARS-CoV-2 Delta variant (B.1.617), constructed and manufactured using the firm's BioXp 3250 synthetic biology benchtop system. The genome can be used by researchers to develop therapies, vaccines, and diagnostics to slow the spread of the variant. Overall, Codex currently offers 13 different SARS-CoV-2 synthetic genomes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.